Cantitate/Preț
Produs

Therapeutic Targeting of RAS Mutant Cancers: Elements in Molecular Oncology

Autor Edward C. Stites, Kendra Paskvan, Shumei Kato
en Limba Engleză Paperback – 14 sep 2022
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
Citește tot Restrânge

Din seria Elements in Molecular Oncology

Preț: 12980 lei

Preț vechi: 13664 lei
-5% Nou

Puncte Express: 195

Preț estimativ în valută:
2484 2613$ 2073£

Carte tipărită la comandă

Livrare economică 09-23 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781009073646
ISBN-10: 1009073648
Pagini: 75
Dimensiuni: 152 x 228 x 3 mm
Greutate: 0.06 kg
Editura: Cambridge University Press
Colecția Cambridge University Press
Seria Elements in Molecular Oncology

Locul publicării:Cambridge, United Kingdom

Cuprins

Introduction; RAS Biology; Oncogenic RAS; RAS Targeting; Downstream Targeting; Upstream Targeting; Targeting Specific RAS Mutants; KRAS G12C Targeting; Direct Targeting of Other RAS Proteins; KRAS G12R Pancreatic Cancer; KRAS G13D Colorectal Cancer; Summary; References.

Descriere

This Element reviews key aspects of RAS biochemistry that are directly relevant to understanding the newly available RAS inhibitors.